Navigation Links
Trius Doses First Patient in Antibacterial Phase 2 Trial
Date:9/21/2008

TR-701 Tested for Efficacy in Drug Resistant Skin Infections

SAN DIEGO, Sept. 22 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the initiation of Phase 2 testing of the oral form of its second-generation oxazolidinone antibacterial drug TR-701. The multicenter trial will test the efficacy, safety and tolerability of once-daily doses of 200, 300 and 400 milligrams of TR-701 in complicated skin and skin structure infections (cSSSI) for five to seven days of treatment.

The study follows the recently completed two-part Phase 1 study that tested the safety, tolerability and pharmacokinetics of TR-701 in single and multiple ascending doses for up to 21 days compared with Zyvox(R) (linezolid), the only marketed drug of the oxazolidinone class. In addition, separate food effect and microdialysis studies measuring the absorption of TR-701 in the presence and absence of food and the tissue penetration of the drug, respectively, have also been completed.

Results of the Phase 1 trials will be presented at the joint annual meetings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, D.C in October 2008.

"Our Phase 1 study results indicate that TR-701 will be a once-daily drug with the potential to offer patients several important advantages over linezolid as well as other marketed drugs," said Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "The intent of Phase 2 will be to validate these observations in a patient population and to select a therapeutic dosing regimen from the three doses being tested."

"The growing epidemic of MRSA in the hospital and community leaves few viable treatment options for patients requiring an oral drug," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "We believe that the once-daily dosing and short course of TR-701 therapy of five to seven days will offer a clinical advantage fo
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. PacificGMP Completes GMP Product Fill for Trius Therapeutics
2. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
5. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
7. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
8. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
9. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
10. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
11. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... NESS ZIONA, Israel , ... today announced that results from a phase I study ... study in advanced Parkinson,s patients, of ND0612, were presented ... Movement Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug ... (SC) delivery patch that would maintain constant levodopa plasma ...
(Date:6/19/2013)... 19, 2013  This year alone, The Leukemia & ... projects with one goal in mind: Discovering lifesaving therapies ... Training" (TNT), a flagship LLS fundraising campaign and the ... marking its landmark 25 th anniversary. To date, ... in research to discover and deliver breakthrough cancer treatments ...
(Date:6/19/2013)... June 19, 2013   Life Technologies Corporation ... licensing agreement granting Suzhou Ribo Life Sciences (Ribo) ... therapeutics in China using ... proprietary siRNA molecules in combination with Invivofectamine® Rx ... human diseases with high unmet medical need in ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4
... events organiser UBM Live , a division of UBM ... CPhI Worldwide and collocated events will be hosted in Madrid, ... for contract and outsourced services and logistics, P-MEC for pharmaceutical ... line-up, InnoPack for pharmaceutical packaging needs. The events will run ...
... 2011 Reportlinker.com announces that a new ... catalogue: Specialty Pharmaceutical Industry ... http://www.reportlinker.com/p0512130/Specialty-Pharmaceutical-Industry---2011-Yearbook.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Specialty Pharmaceutical Industry ... GBI Research,s "Specialty Pharmaceutical ...
Cached Medicine Technology:CPhI Worldwide, ICSE, P-MEC and InnoPack Announce 2012 Events Location 2CPhI Worldwide, ICSE, P-MEC and InnoPack Announce 2012 Events Location 3Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 2Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 3Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 4Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 5Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 6Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 7Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 8Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 9Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 10Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 11Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 12Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 13Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 14Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 15Reportlinker Adds Specialty Pharmaceutical Industry - 2011 Yearbook 16
(Date:6/19/2013)... 19, 2013 Alternatives, a revolutionary new ... to quit using drugs while allowing them to continue ... founders of Alternatives, believe that abstinence-only approaches force people ... treatment and that this approach hurts instead of helping. ... the United States need treatment for addiction but only ...
(Date:6/19/2013)... Kansas City will host its first Ciclovia event on ... A section of Main Street in the midtown area will be ... event. The Main Street Corridor Development and BikeWalkKC ... City join the ranks of dozens of cities across the US ... community vibrancy and active lifestyles. , “Ciclovia is the perfect event ...
(Date:6/19/2013)... Bellingham, Washington (PRWEB) June 19, 2013 ... before physicians deem it medically necessary, according to ... Maternal and Child Health Journal. The results of ... advocating for more than a decade – that ... care, and maintaining a healthy body weight. Fairhaven ...
(Date:6/19/2013)... June 19, 2013 In 2011, the ... EUR 710 million. Generic drugs form the largest sector, ... value. The pharmaceutical industry is a significant contributor to ... the country’s GDP. Approximately 50% of the total domestic ... pharmaceutical industry. Hemofarm, Galenika and Zdravlje Actavis are key ...
(Date:6/19/2013)... today in Menopause International , suggests that ... and less satisfying sex compared to their European ... less likely to access appropriate treatment for a ... first-of-its-kind study, called the CLarifying vaginal atrophy,s impact ... British post-menopausal women with vaginal atrophy are more ...
Breaking Medicine News(10 mins):Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4Health News:Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com 2Health News:British women 50 percent less likley to recieve treatment for common menopausal symptoms 2
... ... Answers Growing Need to Help Safeguard Those with Cognitive,Disorders such as Alzheimer,s and Autism ... Austin, ... embedded and portable surveillance tracking solutions, today announced the launch of a tracking solution ...
... , WASHINGTON , Jan. 27 ... launched "WINHeart -- Score a WIN for Women," an ... diagnosis, treatment and survival of women with cardiovascular disease ... interventional cardiologists within SCAI, today released a new report ...
... severely stressful situations, like those connected to depression and ... in "stress sensitive" brain regions, such as the cingulate ... brain region involved in memory formation. A new ... suggests that chronic insomnia may be another condition associated ...
... new moms, researchers find , WEDNESDAY, Jan. 27 (HealthDay ... cause delayed lactation in new mothers, which means they ... babies, a new study says. , The researchers found ... include such drugs as Prozac and Paxil, may be ...
... ... Leader Provides Payment Platform for Utah’s Answer to Health Care Reform , ... Salt Lake City, UT (Vocus) ... been selected by the State of Utah to provide payment-processing solutions and HSA administration ...
... , Jan. 27 The ... State Department of Children and Families domestic violence lead designated agency ... Jr. , former CEO of United Way of Somerset County ... Hillsborough, New Jersey -based non-profit  501(c)(3) agency. The Bedminster resident,s ...
Cached Medicine News:Health News:FreightWatch Security Net Launches Solution for Tracking and Rescuing Persons at Risk of Wandering 2Health News:FreightWatch Security Net Launches Solution for Tracking and Rescuing Persons at Risk of Wandering 3Health News:FreightWatch Security Net Launches Solution for Tracking and Rescuing Persons at Risk of Wandering 4Health News:New Report and Survey Findings Highlight Why More Women Die From Heart Disease Than Men 2Health News:New Report and Survey Findings Highlight Why More Women Die From Heart Disease Than Men 3Health News:New Report and Survey Findings Highlight Why More Women Die From Heart Disease Than Men 4Health News:New Report and Survey Findings Highlight Why More Women Die From Heart Disease Than Men 5Health News:Losing sleep, losing brain? 2Health News:Antidepressants May Complicate Breast-Feeding 2Health News:HealthEquity Partners with State of Utah to Launch Pilot of Utah Health Exchange 2Health News:HealthEquity Partners with State of Utah to Launch Pilot of Utah Health Exchange 3Health News:The Newly Renamed Resource Center of Somerset Names John Graf, Jr. Director of Development 2Health News:The Newly Renamed Resource Center of Somerset Names John Graf, Jr. Director of Development 3Health News:The Newly Renamed Resource Center of Somerset Names John Graf, Jr. Director of Development 4
... is a two-piece Titanium (Ti-6Al-4V) screw offered ... a variety of lengths. The two pieces ... sterile packaged. A single instrument set contains ... of both Standard and Mini Kompressor Compression ...
... combined with the IRIS Medical OcuLight ... consoles,the EasyView slit lamp adapter (SLA) ... laser photocoagulation,to your existing Haag-Streit slit ... and glaucoma,without compromising the diagnostic functions ...
All purpose, low profile punches with a large square bite....
... ratchet design provides fingertip ratchet disengagement allowing ... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ...
Medicine Products: